# Techcyte **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** digital pathology, AI diagnostics, computer vision, clinical and anatomic pathology, veterinary diagnostics, life sciences **Stage:** Private, late growth; $15M raise closed April 2026 **Location:** Orem, UT **Updated:** 2026-06-18 **Needs-reviewed:** 2026-06-18 **Hero:** https://picsum.photos/seed/techcyte-digital-pathology-fusion-2026/1600/1100 **Pull:** *AI that reads digitized slides so scarce pathologists can spend their time on the hard cases.* ## Summary Techcyte is an Orem, Utah company building AI-powered digital-pathology software. Its Fusion platform is a browser-based system that unifies anatomic pathology (tissue sections) and clinical pathology (blood, urine, cytology) workflows, integrates with lab systems, and layers AI on top of digitized slides. The company is led by CEO Ben Cahoon and works across human clinical labs, veterinary diagnostics, and related testing markets. [source:techcyte-official-website] For the Great Work Utah wiki, Techcyte is a real, shipping medical-AI company operating at clinical scale from Utah County rather than a coastal AI hub. ## Impact Pathology is a diagnostic bottleneck: cancer diagnoses, infection workups, and hematology all typically require a trained human at a microscope, and pathologists are scarce and unevenly distributed. Software that automates the first pass — pre-classifying cells, flagging slides, standardizing analysis across sites, and routing cases efficiently — can reduce time-to-diagnosis and extend pathology capacity to labs too small to staff a full-time specialist. Techcyte's stated impact mechanism is augmentation rather than autonomous diagnosis: it supports and accelerates human pathologists by digitizing and standardizing the workflow. The value lands as faster turnaround, broader access, and more consistent analysis across reviewers and sites. ## What They Are Building The current flagship is Fusion, which Techcyte describes as a unified, open digital-pathology platform spanning anatomic and clinical workflows, with a partner program that integrates third-party AI tools (for example, prostate diagnostics, slide QC, and mitotic counting from partner companies). Getting historically separate anatomic and clinical pathology workflows to share infrastructure, models, and data is the core technical challenge. A central asset for the AI roadmap is data. Techcyte's April 2026 financing included access to a Mayo Clinic Safe Harbor dataset of more than 17 million de-identified slides and pathology reports, intended to improve the accuracy of Fusion's AI. [source:techcyte-official-website] ## What They Need Now Likely needs include machine-learning engineers with computer-vision backgrounds who want to work on real medical data at scale, pathology domain experts (MD or PhD) willing to work on the technology side, biomedical-informatics and integration engineers, and commercial and regulatory staff to drive adoption and clearances. The company has framed its 2026 raise around growth and a path to profitability rather than top-line growth alone, so operators who can improve unit economics fit the moment. For talent matching, Techcyte fits people who want to ship clinical-grade medical AI, on real lab data, while staying in Utah — and who prefer a deployed-product environment over basic research. ## Who Could Help Useful helpers include FDA regulatory consultants experienced with AI/ML-based diagnostic software (SaMD), health-system and reference-lab commercial partners, scanner and hardware integration partners, and growth-stage investors or strategics comfortable with regulated medical AI. The existing strategic relationships with Mayo Clinic and Zoetis shape both its data advantage and its likely partnership and exit dynamics. ## Utah Context Techcyte is one of the more substantial healthcare-AI companies headquartered in Utah County, a region dominated by SaaS. It originated as a University of Utah–linked spinout and has grown into a clinically deployed platform with strategic backing from Mayo Clinic and Zoetis. For Utah's life-sciences story, it is a useful example of medical AI built on domain partnerships and proprietary data rather than pure model research, and a landing spot for ML talent that wants healthcare impact without leaving the state. ## Evidence - [Source: Techcyte Official Website and 2026 Capital-Raise Announcement](techcyte-official-website.md) ## Open Questions - Revenue, headcount, and the mix of FDA-cleared versus research-use-only deployments are not confirmed from primary sources in this pass; commonly cited figures (e.g., ~$15M revenue, ~120 employees, ~9M scans per year) come from secondary coverage and should be verified. - The AI-pathology market is consolidating, with better-funded national players (PathAI, Paige, Proscia) pursuing autonomous-diagnostic clearances; Techcyte's differentiation rests on breadth and its Mayo/Zoetis relationships rather than frontier models. - With strategics rather than venture investors leading the cap table, acquisition may be a more likely outcome than independent scaling — relevant to anyone weighing a long-term role. - Imagery is a deterministic placeholder. A license-cleared product screenshot or facility photograph approved by the company should replace it before this renders as a marquee page.